Oligo Synthesis : CEPs
Prices quoted are for single packs only. For multiples of the same product please request a quote. Some of Glen"sproductsarehazardousandmay be subject to additional shipping charges. Full product information is available onGlen Research"s website.
5"-OMe-dT-CE Phosphoramidite
5"-OMe-dT-CE Phosphoramidite
Glen Research
| Catalogue No. | Description | Pack Size | Price | Qty |
|
|---|---|---|---|---|---|
| 10-1031-02 | 5"-OMe-dT-CE Phosphoramidite | 0.25g | £284.00£269.80Offer until : 31-Mar-2021Offer Code : GLEN5View Offer | Quantity | Add to Order |
| 10-1031-90 | 5"-OMe-dT-CE Phosphoramidite | 100µmoles | £108.00£102.60Offer until : 31-Mar-2021Offer Code : GLEN5View Offer | Quantity | Add to Order |
Related products
5"-OMe-dT-CE Phosphoramidite
5"-OMe-dT-CE Phosphoramidite
Glen Research
| 5"-OMe-dT-CE Phosphoramidite |
Catalog Number: 10-1031-xx
Description: 5"-OMe-dT-CE Phosphoramidite
| 5"-O-methyl-2"-deoxyThymidine,3"-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite | ||
| Formula: C20H33N4O6P | M.W.: 456.48 | F.W.: 318.22 |
Diluent: Anhydrous AcetonitrileAdd fresh diluent to product vial to recommended concentration and swirl vial occasionally over several minutes until product is completely dissolved. (Some oils may require between 5 and 10 minutes.) Use care to maintain anhydrous conditions. In case of transfer to alternate vial type, ensure recipient vial has been pre-dried. For more information, see http://www.glenres.com/ Technical/TB_ABITransfer.pdf. |
| Coupling: No changes needed from standard method recommended by synthesizer manufacturer. |
| Deprotection: No changes needed from standard method recommended by synthesizer manufacturer.(Note: this product is a 5"-terminator.) |
| Storage: Freezer storage, -10 to -30°C, dry |
| Stability in Solution: 24 hours |
chain terminators
In situations where ligation must be blocked at the 5’ terminus, 5’-OMe-dT may be used. 5’-OMe modification of a strand of siRNA using 5’-OMe-T can control guide strand selection and targeting specificity.1 5’-Amino-dT terminates an oligonucleotide with a 5’-amino group which may be used for attaching a peptide or a PNA sequence. To avoid polymerase extension at the 3’ terminus, 2’,3’-dideoxynucleoside and 3’-deoxynucleoside CPGs have proved to be effective. 2’,3’- Phosphoramidites are designed to be used with the 5’-phosphoramidites and supports. Since these phosphoramidites have no DMT group, they are not compatible with purification by the DMT-on technique. Ion exchange HPLC or PAGE should be used to purify these dideoxy terminated oligos to ensure that shorter sequences (containing 3’-OH) groups are removed. (3’-Termination can also be effected using a 3’-3’ linkage formed using 5’-supports, or 3’-spacer C3 CPG.)
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
5"-OMe-dT-CE Phosphoramidite
5"-OMe-dT-CE Phosphoramidite
Glen Research
MSDS
| Glen Report 20.1: Technical Brief - New application for 5Õ-OMe-dT phosphoramidite |
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
5"-OMe-dT-CE Phosphoramidite
5"-OMe-dT-CE Phosphoramidite
Glen Research
In situations where ligation must be blocked at the 5" terminus, 5"-OMe-dT may be used.
EXTINCTION DATA
| Item | Nucleoside | λMax-1 | Emax-1 | λMax-2 | Emax-2 | E260 |
| (nm) | (ml/µmole) | nm | (ml/µmole) | (ml/µmole) | ||
| 10-1031 | 5"-OMe-dT | 266 | 9.0 | 8.3 |
DILUTION/COUPLING DATA
The table below shows pack size data and, for solutions, dilutions and approximate couplings based on normal priming procedures.
| ABI 392/394 | |||||||||
| Cat.No. | PackSize | Grams/Pack | 0.1M Dil.(mL) | LV40 | LV200 | 40nm | 0.2µm | 1µm | 10µm |
| Approximate Number of Additions | |||||||||
| 10-1031-02 | 0.25grams | .25grams | 5.48 | 169.33 | 101.6 | 63.5 | 46.18 | 33.87 | 8.47 |
| 10-1031-90 | 100µmoles | .046grams | 1 | 20 | 12 | 7.5 | 5.45 | 4 | 1 |
| Expedite | |||||||||
| Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 50nm | 0.2µm | 1µm | 15µm | |
| Approximate Number of Additions | |||||||||
| 10-1031-02 | 0.25grams | .25grams | 8.17 | .07 | 157 | 98.13 | 71.36 | 9.81 | |
| 10-1031-90 | 100µmoles | .046grams | 1.5 | .07 | 23.6 | 14.75 | 10.73 | 1.48 | |
| Beckman | |||||||||
| Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 30nm | 200nm | 1000nm | ||
| Approximate Number of Additions | |||||||||
| 10-1031-02 | 0.25grams | .25grams | 8.17 | .07 | 158.6 | 99.13 | 72.09 | ||
| 10-1031-90 | 100µmoles | .046grams | 1.5 | .07 | 25.2 | 15.75 | 11.45 | ||
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
AthensResearch&Technology公司位于美国乔治亚州雅典市，从1986年以来一直致力于纯化高纯度，高活性的人类蛋白质和开发这些蛋白的多克隆抗血清。我们的常规产品包括丝氨酸蛋白酶、蛋白酶抑制剂、中性粒细胞酶、载脂蛋白、脂蛋白，血小板蛋白、转铁蛋白、免疫球蛋白等。二十年多年来，世界各地的研究人员都在使用我们公司的产品。在炎症、冠状动脉疾病、自身免疫性疾病、癌症、老年痴呆症等等研究的主要科学出版物中都能看到引用我们公司的产品。我们提供优质，可靠的产品和出色的客户服务。我们期待着您的业务。如果需要定制研究服务，AthensResearch&Technology公司能够根据您的项目要求提供无与伦比的试剂。
公司主要产品：一、凝血因子相关系列产品：包括多款从人血浆、血小板中分离纯化的凝血因子相关蛋白。二、酶及抑制剂系列产品：包括多款从人血浆、红细胞分离纯化的a-抗糜蛋白酶、a1/2抗胰蛋白酶、抗凝血酶、C1酯酶抑制因子、Calpain-1等酶及其抑制剂产品。三、免疫球蛋白系列产品：包括多款从人血浆、骨髓瘤、初乳以及狗和小鼠血浆中分离纯化的免疫球蛋白产品。四、脂蛋白及载脂蛋白系列产品：包括包括多款从人血浆中分离纯化的载脂蛋白及脂蛋白（高密度、中等密度、低密度、极低密度脂蛋白）产品。五、低内毒素蛋白系列产品：包括多款适宜于细胞培养的低内毒素脂蛋白、免疫球蛋白及转铁蛋白产品。六、乳蛋白系列产品：包括从人乳中分离纯化的乳白蛋白、乳铁传递蛋白及分泌型免疫球蛋白A。七、中性粒细胞源蛋白系列产品：包括多款纯化分离自人中性粒细胞的Azurocidin 、CathepsinG及Lactoferrin等蛋白产品。八、血小板相关系列产品：包括纯化分离自人血小板的血小板因子4及凝血酶致敏蛋白。九、转铁蛋白及脱铁转铁蛋白（APOTRANSFERRINS）系列产品：包括多款纯化分离自人、大小鼠、狗及食蟹猴血浆中的转铁蛋白/脱铁转铁蛋白，可应用于细胞或组织培养。十、抗体系列产品：包括多款兔、大鼠、羊源的多克隆抗体产品。
ebiomall.com
